Skip to content
OpenCapital
Get started

Tenet Healthcare THC Debt - Unamortized Discount (Premium) and Issuance Costs, Net

Debt - Unamortized Discount (Premium) and Issuance Costs, Net at other companies

STERIS logo
STERISSTE
——
Leidos Holdings logo
Leidos HoldingsLDOS
——

Other financials

Income statement

See full
Revenue$5.4B+2.8%
Operating income$1.3B+37.4%
Net income$906.0M+45.7%
EPS (diluted)$8.01+87.6%

Balance sheet

See full
Cash & equivalents$3.0B-1.1%
Total debt$13.3B+0.2%
Total equity$4.8B+15.1%
Total assets$31.2B+6.7%

Cash flow

See full
Operating cash flow$1.6B+101%
CapEx$180.0M+4.0%
Free cash flow$1.5B+128%

Valuation

See full
Market cap$14.86B—
Enterprise value$25.19B—
P/E5.6×—
P/S0.7×—

Profitability

See full
Operating margin18%+0.4pp
Net margin12.4%+0.9pp
FCF margin15.6%—

Returns & leverage

See full
Return on equity58.9%-2.7pp
Debt / equity2.8×-0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Tenet Healthcare in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: Tenet Healthcare’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tenet Healthcare's debt - unamortized discount (premium) and issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tenet Healthcare's debt - unamortized discount (premium) and issuance costs, net?
Tenet Healthcare (THC) reported debt - unamortized discount (premium) and issuance costs, net of $89M in Q1 2026.
How has Tenet Healthcare's debt - unamortized discount (premium) and issuance costs, net changed year-over-year?
Tenet Healthcare's debt - unamortized discount (premium) and issuance costs, net decreased by 0.0% year-over-year, from $89M to $89M.
What is the long-term trend for Tenet Healthcare's debt - unamortized discount (premium) and issuance costs, net?
Over 3 years (2022 to 2025), Tenet Healthcare's debt - unamortized discount (premium) and issuance costs, net has grown at a -10.5% compound annual growth rate (CAGR), from $131M to $94M.